Five Prime Therapeutics, Inc. (NASDAQ:FPRX)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group LLC in a report released on Thursday. They presently have a $52.00 price target on the biotechnology company’s stock, down from their previous price target of $55.00. Jefferies Group LLC’s price objective would indicate a potential upside of 82.39% from the company’s previous close.

A number of other research firms have also issued reports on FPRX. Zacks Investment Research raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Wednesday, April 26th. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Five Prime Therapeutics currently has an average rating of “Hold” and a consensus target price of $60.80.

Shares of Five Prime Therapeutics (NASDAQ FPRX) opened at 28.51 on Thursday. The stock’s market capitalization is $795.34 million. The company has a 50-day moving average of $29.71 and a 200-day moving average of $34.92. Five Prime Therapeutics has a 12-month low of $26.27 and a 12-month high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by $0.43. The company had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. Five Prime Therapeutics had a negative return on equity of 30.52% and a negative net margin of 356.39%. Five Prime Therapeutics’s revenue for the quarter was down 16.1% compared to the same quarter last year. During the same period last year, the company earned ($0.49) earnings per share. Equities analysts expect that Five Prime Therapeutics will post ($4.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics, Inc. (FPRX) Given “Buy” Rating at Jefferies Group LLC” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/10/five-prime-therapeutics-inc-fprx-given-buy-rating-at-jefferies-group-llc.html.

A number of institutional investors have recently added to or reduced their stakes in FPRX. Creative Planning increased its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares in the last quarter. Laurion Capital Management LP purchased a new position in Five Prime Therapeutics during the first quarter worth approximately $210,000. Rockefeller Financial Services Inc. purchased a new position in Five Prime Therapeutics during the second quarter worth approximately $210,000. BlueCrest Capital Management Ltd purchased a new position in Five Prime Therapeutics during the first quarter worth approximately $254,000. Finally, Arxis Securities LLC purchased a new position in Five Prime Therapeutics during the first quarter worth approximately $267,000. Hedge funds and other institutional investors own 85.10% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.